FTC drug divestiture policy may reduce competition, study finds

Last month, Novartis completed its $11 billion acquisition of Avidity Biosciences-the latest in a string of major pharmaceutical mergers including Merck’s acquisition of Verona Pharma and GSK’s acquisition of RAPT Therapeutics.